bortezomib/dexamethasone

DRUG3 trials

Sponsors

La Jolla Pharmaceutical Company, Samsung Medical Center, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Acquired Pure Red Cell AplasiaMultiple MyelomaRelapsed and/or Refractory Cutaneous T-cell Lymphoma

Phase 1

Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

TerminatedNCT00609817

La Jolla Pharmaceutical CompanyMultiple Myeloma

Start: 2008-05-31End: 2009-04-30Updated: 2013-06-25

Phase 2

Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma

CompletedNCT03487133

Samsung Medical CenterRelapsed and/or Refractory Cutaneous T-cell Lymphoma

Start: 2017-09-19End: 2020-09-30Updated: 2020-10-26

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

CompletedNCT04423367

Institute of Hematology & Blood Diseases Hospital, ChinaAcquired Pure Red Cell Aplasia

Start: 2020-09-13End: 2024-09-30Updated: 2026-02-11

Related Papers

Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study.

2025-08-07